Home › Funds › Morgan Stanley › BCLI
Morgan Stanley position in BCLI
BRAINSTORM CELL THERAPEUTICS
Latest position (Q2 2025)5.80K sh
Reported value held$6.50K
Portfolio Weight0.00%
First reportedQ3 2021
Last changeAdd
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2021 | 52.51K | $174.00K | New |
| Q4 2021 | 51.66K | $207.00K | Reduce |
| Q1 2022 | 49.11K | $164.00K | Reduce |
| Q2 2022 | 40.98K | $113.00K | Reduce |
| Q3 2022 | 36.52K | $162.00K | Reduce |
| Q4 2022 | 24.10K | $39.52K | Reduce |
| Q1 2023 | 38.83K | $128.14K | Add |
| Q2 2023 | 28.94K | $59.61K | Reduce |
| Q3 2023 | 30.55K | $6.12K | Add |
| Q4 2023 | 51.45K | $14.05K | Add |
| Q1 2024 | 40.10K | $22.64K | Reduce |
| Q2 2024 | 36.98K | $12.52K | Reduce |
| Q3 2024 | 49.46K | $11.39K | Add |
| Q4 2024 | 4.32K | $9.80K | Reduce |
| Q1 2025 | 4.34K | $5.47K | Hold |
| Q2 2025 | 5.80K | $6.50K | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.